Singapore markets closed

BioMarin Pharmaceutical Inc. (0HNC.L)

LSE - LSE Delayed Price. Currency in USD
Add to watchlist
87.27-1.21 (-1.37%)
At close: 07:13PM GMT
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.31
52-week change 3-6.17%
S&P500 52-week change 327.86%
52-week high 399.65
52-week low 376.29
50-day moving average 390.32
200-day moving average 389.61

Share statistics

Avg vol (3-month) 35.97k
Avg vol (10-day) 310.44k
Shares outstanding 5178.06M
Implied shares outstanding 6N/A
Float 8187.26M
% held by insiders 10.68%
% held by institutions 1101.51%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 6.93%
Operating margin (ttm)4.37%

Management effectiveness

Return on assets (ttm)1.63%
Return on equity (ttm)3.51%

Income statement

Revenue (ttm)2.42B
Revenue per share (ttm)12.88
Quarterly revenue growth (yoy)20.20%
Gross profit (ttm)N/A
EBITDA 276.48M
Net income avi to common (ttm)167.64M
Diluted EPS (ttm)0.22
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)1.07B
Total cash per share (mrq)5.69
Total debt (mrq)1.13B
Total debt/equity (mrq)22.90%
Current ratio (mrq)2.51
Book value per share (mrq)26.25

Cash flow statement

Operating cash flow (ttm)159.26M
Levered free cash flow (ttm)-25.9M